Home » Stocks » BCRX

BioCryst Pharmaceuticals, Inc. (BCRX)

Stock Price: $11.96 USD -0.53 (-4.24%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $11.95 -0.01 (-0.08%) May 13, 7:55 PM
Market Cap 2.14B
Revenue (ttm) 32.05M
Net Income (ttm) -209.50M
Shares Out 177.34M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $11.96
Previous Close $12.49
Change ($) -0.53
Change (%) -4.24%
Day's Open 12.51
Day's Range 11.84 - 12.61
Day's Volume 3,142,429
52-Week Range 3.30 - 14.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

RESEARCH TRIANGLE PARK, N.C., May 12, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency...

1 day ago - GlobeNewsWire

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

6 days ago - Zacks Investment Research

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) reported a first-quarter loss of $0.36, wider than the consensus loss of $0.27 and deeper than the EPS loss of $0.24 reported a year ago mainly driven by high...

1 week ago - Benzinga

The drugmaker reported better-than-expected Q1 results.

1 week ago - The Motley Fool

BioCryst (BCRX) delivered earnings and revenue surprises of -38.46% and 48.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

—Q1 2021 ORLADEYO ™ (berotralstat) net revenue of $10.9 million—

1 week ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO™ (...

1 week ago - GlobeNewsWire

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

RESEARCH TRIANGLE PARK, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Th...

3 weeks ago - GlobeNewsWire

Investors cheered good news out of Japan for the company's lead product.

4 weeks ago - The Motley Fool

—ORLADEYO is the first and only approved prophylactic therapy for HAE in Japan—

4 weeks ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare ...

1 month ago - GlobeNewsWire

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) announced results from a dose-ranging trial evaluating BCX9930 in treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH) patients and PNH patients with an...

1 month ago - Benzinga

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) announced results from a dose-ranging trial evaluating BCX9930 in treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH) patients and PNH patients with an ...

1 month ago - Benzinga

Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest ...

Other stocks mentioned: BMY, PFE, MRKR, PCRX, PRQR, RUBY, ZEAL
1 month ago - Benzinga

RESEARCH TRIANGLE PARK, N.C., March 19, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Helen Thackray, M.D., FAAP, to the newly crea...

1 month ago - GlobeNewsWire

For investors and media only

2 months ago - GlobeNewsWire

With the trading day about halfway over, the broad markets came roaring back to start out the week.

Other stocks mentioned: EDIT, GRPN, RUN, TWTR
2 months ago - 24/7 Wall Street

The European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion backing the approval of BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) ORLADEYO (berotralstat) for ro...

2 months ago - Benzinga

The company's fourth-quarter earnings report did not pass muster.

2 months ago - The Motley Fool

BioCryst (BCRX) delivered earnings and revenue surprises of -36.00% and -72.72%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2020 financial...

3 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that data on ORLADEYO™ (berotralstat) will be presented at the 2021 American...

3 months ago - GlobeNewsWire

In less than several weeks, BioCryst Pharmaceuticals (NASDAQ: BCRX) shares have advanced from $7.2 above $12, and the current price stands around $10.2. According to the latest news, the FDA approved Ra...

3 months ago - Invezz

Voyager Therapeutics (NASDAQ: VYGR) shares are trading lower Wednesday after the company announced that the FDA had notified Neurocrine that it placed a clinical hold on the RESTORE-1 clinical trials of...

Other stocks mentioned: OCGN, VYGR
3 months ago - Benzinga

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares jump after the FDA approved supplemental marketing application seeking approval for RAPIVAB (peramivir injection) to treat acute uncomplicated influenz...

3 months ago - Benzinga

RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental...

3 months ago - GlobeNewsWire

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares, which had been locked in a trading range since the start of January, broke out of the range Monday and rallied strongly, only to pull back in the ne...

3 months ago - Benzinga

RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted sev...

3 months ago - GlobeNewsWire

BioCryst Pharmaceuticals surged 39% to a five-year high on Monday as Reddit investors declared a "BioWar" against short-sellers betting against the stock. The move followed a post on the r/WallStreetBet...

3 months ago - Business Insider

Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

BioCryst (BCRX) gets approval in Japan for oral, once-daily Orladeyo 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years or older.

3 months ago - Zacks Investment Research

Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science tools focu...

Other stocks mentioned: FLDM, SEEL, ADMP
3 months ago - Benzinga

RESEARCH TRIANGLE PARK, N.C., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted m...

3 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 ...

4 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conf...

4 months ago - GlobeNewsWire

BioCryst (BCRX) will discontinue the study on its pipeline candidate, galidesivir, for treating patients with the novel coronavirus disease (COVID-19).

4 months ago - Zacks Investment Research

Both stocks are in the early stage of a long-term growth trajectory.

Other stocks mentioned: CYRX
4 months ago - The Motley Fool

VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher after Maxim raised its price target on the stock from $3 to $5. VistaGen Therapeutics is a biotechnology firm.

Other stocks mentioned: TDOC, VTGN
4 months ago - Benzinga

Investors were disappointed by the biotech's COVID-19 clinical trial results.

4 months ago - The Motley Fool

RESEARCH TRIANGLE PARK, N.C., Dec. 22, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, ga...

4 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Dec. 21, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that in a Phase 1 clinical trial with BCX9250, an oral activin receptor-like...

4 months ago - GlobeNewsWire

The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U.S. popula...

Other stocks mentioned: HALO, QDEL, TDOC, XLRN
4 months ago - Zacks Investment Research

—Direct to patient shipments of the first oral, once-daily prophylactic treatment underway through Optime Care —  

4 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the JMP Securities Hematology Summit, which...

5 months ago - GlobeNewsWire

BioCryst received FDA approval for Orladeyo last week. The company quickly moved to raise cash and remove the financing overhang.

5 months ago - Seeking Alpha

BioCryst (BCRX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has received a price target increase from $13 to $14 by H.C. Wainwright.

5 months ago - Pulse2

About BCRX

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial ... [Read more...]

Industry
Biotechnology
IPO Date
Mar 3, 1994
CEO
Jon Stonehouse
Employees
246
Stock Exchange
NASDAQ
Ticker Symbol
BCRX
Full Company Profile

Financial Performance

In 2020, BCRX's revenue was $17.81 million, a decrease of -63.53% compared to the previous year's $48.84 million. Losses were -$182.81 million, 67.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for BCRX stock is "Buy." The 12-month stock price forecast is 16.56, which is an increase of 38.46% from the latest price.

Price Target
$16.56
(38.46% upside)
Analyst Consensus: Buy